Literature DB >> 1936296

Complications of radical hysterectomy in women with early stage cervical cancer: clinical analysis of 270 cases.

A Ayhan1, Z S Tuncer, H Yarali.   

Abstract

During a 25 year period, 270 cases of stage IB and IIA cervical cancer were subjected to radical hysterectomy and lymphadenectomy. The morbidity rate was 27.6% and mortality rate was 0.3%. While injuries to the great vessels were the most common intra-operative complications, the most frequent postoperative complications were in the urinary system. The leading causes of morbidity were bladder dysfunction (16.2%), urinary infection (5.9%), lymphocyst (6.4%) and wound infections (3.5%). While the overall complications seem high, the frequency of serious morbidity has diminished and radical hysterectomy now represents one of the accepted methods of treatment of cervical carcinoma, with good 5-year survival rates.

Entities:  

Mesh:

Year:  1991        PMID: 1936296

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

1.  Radical hysterectomy with pelvic lymphadenectomy: indications, technique, and complications.

Authors:  Rachel A Ware; John R van Nagell
Journal:  Obstet Gynecol Int       Date:  2010-09-01

2.  Postoperative surgical complications of lymphadenohysterocolpectomy.

Authors:  F Marin; M Pleşca; C I Bordea; S C Voinea; I Burlănescu; E Ichim; C G Jianu; R R Nicolăescu; M P Teodosie; K Maher; A Blidaru
Journal:  J Med Life       Date:  2014-03-25

3.  Class I versus Class III radical hysterectomy in stage IB1 (tumor ≤ 2 cm) cervical cancer: a matched cohort study.

Authors:  Wei Wang; Chun-Liang Shang; Qi-Qiao Du; Di Wu; Yan-Chun Liang; Tian-Yu Liu; Jia-Ming Huang; Shu-Zhong Yao
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

4.  Laparoscopic procedure compared with open radical hysterectomy with pelvic lymphadenectomy in early cervical cancer: a retrospective study.

Authors:  Jianfeng Guo; Lu Yang; Jing Cai; Linjuan Xu; Jie Min; Yi Shen; Zhoufang Xiong; Weihong Dong; Vichitra Bunyamanop; Zehua Wang
Journal:  Onco Targets Ther       Date:  2018-09-18       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.